Johnson & Johnson Share Holder Equity 2012-2025 | JNJ
Johnson & Johnson share holder equity from 2012 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
- Johnson & Johnson share holder equity for the quarter ending December 31, 2025 was $79.277B, a 13% increase year-over-year.
- Johnson & Johnson share holder equity for 2024 was $71.49B, a 3.95% increase from 2023.
- Johnson & Johnson share holder equity for 2023 was $68.774B, a 10.46% decline from 2022.
- Johnson & Johnson share holder equity for 2022 was $76.804B, a 3.76% increase from 2021.
|
Johnson & Johnson Annual Share Holder Equity (Millions of US $) |
|
|---|---|
| 2024 | $71,490 |
| 2023 | $68,774 |
| 2022 | $76,804 |
| 2021 | $74,023 |
| 2020 | $63,278 |
| 2019 | $59,471 |
| 2018 | $59,752 |
| 2017 | $60,160 |
| 2016 | $70,418 |
| 2015 | $71,150 |
| 2014 | $69,752 |
| 2013 | $74,053 |
| 2012 | $64,826 |
| 2011 | $57,080 |
|
Johnson & Johnson Quarterly Share Holder Equity (Millions of US $) |
|
|---|---|
| 2025-09-30 | $79,277 |
| 2025-06-30 | $78,473 |
| 2025-03-31 | $78,109 |
| 2024-12-31 | $71,490 |
| 2024-09-30 | $70,158 |
| 2024-06-30 | $71,538 |
| 2024-03-31 | $70,020 |
| 2023-12-31 | $68,774 |
| 2023-09-30 | $71,228 |
| 2023-06-30 | $76,409 |
| 2023-03-31 | $70,869 |
| 2022-12-31 | $76,804 |
| 2022-09-30 | $74,599 |
| 2022-06-30 | $76,357 |
| 2022-03-31 | $74,709 |
| 2021-12-31 | $74,023 |
| 2021-09-30 | $70,272 |
| 2021-06-30 | $69,580 |
| 2021-03-31 | $65,834 |
| 2020-12-31 | $63,278 |
| 2020-09-30 | $64,473 |
| 2020-06-30 | $62,978 |
| 2020-03-31 | $61,294 |
| 2019-12-31 | $59,471 |
| 2019-09-30 | $58,210 |
| 2019-06-30 | $60,785 |
| 2019-03-31 | $58,955 |
| 2018-12-31 | $59,752 |
| 2018-09-30 | $64,626 |
| 2018-06-30 | $62,889 |
| 2018-03-31 | $63,255 |
| 2017-12-31 | $60,160 |
| 2017-09-30 | $73,979 |
| 2017-06-30 | $71,922 |
| 2017-03-31 | $70,341 |
| 2016-12-31 | $70,418 |
| 2016-09-30 | $72,769 |
| 2016-06-30 | $72,473 |
| 2016-03-31 | $72,647 |
| 2015-12-31 | $71,150 |
| 2015-09-30 | $71,554 |
| 2015-06-30 | $71,131 |
| 2015-03-31 | $67,878 |
| 2014-12-31 | $69,752 |
| 2014-09-30 | $76,591 |
| 2014-06-30 | $78,048 |
| 2014-03-31 | $76,582 |
| 2013-12-31 | $74,053 |
| 2013-09-30 | $69,804 |
| 2013-06-30 | $69,665 |
| 2013-03-31 | $66,855 |
| 2012-12-31 | $64,826 |
| 2012-09-30 | $63,761 |
| 2012-06-30 | $60,434 |
| 2012-03-31 | $61,366 |
| 2011-12-31 | $57,080 |
| 2011-09-30 | $61,527 |
| 2011-06-30 | $62,132 |
| 2011-03-31 | $59,863 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $526.407B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1027.991B | 49.45 |
| AbbVie (ABBV) | United States | $385.484B | 23.08 |
| Roche Holding AG (RHHBY) | Switzerland | $349.042B | 0.00 |
| Novartis AG (NVS) | Switzerland | $306.301B | 16.24 |
| Novo Nordisk (NVO) | Denmark | $277.857B | 16.29 |
| Merck (MRK) | United States | $270.987B | 12.62 |
| Pfizer (PFE) | United States | $148.397B | 8.16 |
| Sanofi (SNY) | France | $113.414B | 10.97 |
| Bayer (BAYRY) | Germany | $50.732B | 8.90 |
| Innoviva (INVA) | United States | $1.476B | 7.39 |